Immunotherapy, the strategy for triggering the patient's own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival ...
Dec 4, 2018
0
5
(HealthDay)—Thermal ablation (TA) is a safe, effective treatment for stage 1 non-small cell lung cancer (NSCLC), according to a study recently published in Radiology.
Oct 24, 2018
0
0
Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, MD, the Huizenga Family Endowed Chair in Oncology Research ...
Sep 24, 2018
0
4
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.
Aug 21, 2018
0
318
Testing for dozens of genetic mutations in tumors of patients with a common form of advanced lung cancer did not appear to improve survival compared to routine genetic testing, a study led by Yale Cancer Center (YCC) scientists ...
Aug 8, 2018
0
47
Differences in the active treatment of lung cancer across England may be cutting short the lives of hundreds of patients with the disease every year, concludes research published online in the journal Thorax.
Mar 6, 2018
0
7
(HealthDay)—From 1997 to 2014, improvements in cancer survival were mainly limited to patients with private or Medicare insurance, according to a study published online Nov. 30 in JAMA Oncology.
Dec 4, 2017
0
1
New research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy (CT) treatment based on their specific BRCA1 expression levels, as opposed to providing ...
Oct 17, 2017
0
0
A new analysis finds that, despite advances in care, men and women with a diagnosis of heart failure continue to have worse survival rates than patients with certain common cancers.
May 4, 2017
0
0
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data ...
Apr 3, 2017
0
1
